{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:54:09Z","timestamp":1777863249832,"version":"3.51.4"},"reference-count":15,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"unspecified","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2024,12,7]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>A middle childhood boy with epilepsy exhibited persistent low concentrations of valproic acid, lamotrigine and topiramate for over 1 month, primarily due to pharmacokinetic interactions involving fosphenytoin, meropenem and phenobarbital. Awareness of these clinically significant interactions is crucial for ensuring effective seizure control. However, further research is needed to establish optimal evidence-based treatment strategies in complex paediatric cases.<\/jats:p>","DOI":"10.1136\/bcr-2024-261648","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T08:40:28Z","timestamp":1738140028000},"page":"e261648","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Persistent low concentrations of antiepileptics in a critically ill paediatric patient: an example of multiple potential drug interactions"],"prefix":"10.1136","volume":"18","author":[{"given":"Lone Bak","family":"Posada","sequence":"first","affiliation":[{"name":"Clinical Pharmacology, Aalborg University Hospital, Aalborg, Region Nordjylland, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9365-1918","authenticated-orcid":false,"given":"Anne Estrup","family":"Olesen","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Aalborg University Hospital, Aalborg, Region Nordjylland, Denmark"},{"name":"Faculty of Medicine, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tine H\u00f8g","family":"S\u00f8rensen","sequence":"additional","affiliation":[{"name":"Paediatrics, Aalborg University Hospital, Aalborg, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4294-0124","authenticated-orcid":false,"given":"Samuel","family":"Azuz","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Aalborg University Hospital, Aalborg, Region Nordjylland, Denmark"},{"name":"Faculty of Medicine, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"key":"2025082800420213000_18.1.e261648.1","doi-asserted-by":"crossref","first-page":"232640981878838","DOI":"10.1177\/2326409818788382","article-title":"An Adapted Clinical Measurement Tool for the Key Symptoms of CLN2 Disease","volume":"6","author":"Wyrwich","year":"2018","journal-title":"J Inborn Errors Metab Screen"},{"key":"2025082800420213000_18.1.e261648.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(03)00409-5"},{"key":"2025082800420213000_18.1.e261648.3","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s40272-018-0302-4","article-title":"Pharmacokinetics and Drug Interaction of Antiepileptic Drugs in Children and Adolescents","volume":"20","author":"Iapadre","year":"2018","journal-title":"Pediatr Drugs"},{"key":"2025082800420213000_18.1.e261648.4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejpn.2014.12.010","article-title":"Pharmacological interaction between valproic acid and carbapenem: what about levels in pediatrics?","volume":"19","author":"Miranda Herrero","year":"2015","journal-title":"Eur J Paediatr Neurol"},{"key":"2025082800420213000_18.1.e261648.5","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/FTD.0000000000000316","article-title":"The Effect of Different Carbapenem Antibiotics (Ertapenem, Imipenem\/Cilastatin, and Meropenem) on Serum Valproic Acid Concentrations","volume":"38","author":"Wu","year":"2016","journal-title":"Ther Drug Monit"},{"key":"2025082800420213000_18.1.e261648.6","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009334377"},{"key":"2025082800420213000_18.1.e261648.7","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.pediatrneurol.2013.03.022","article-title":"Seizures from valproate-carbapenem interaction","volume":"49","author":"Taha","year":"2013","journal-title":"Pediatr Neurol"},{"key":"2025082800420213000_18.1.e261648.8","unstructured":"Van der Merwe F , Wallis S , Udy A . Understanding the impact of critical illness on drug pharmacokinetics - scientifically robust study design. Clin Toxicol 2011."},{"key":"2025082800420213000_18.1.e261648.9","doi-asserted-by":"crossref","unstructured":"Jansen MJ , Williams LL , Wang SH , et al . Bowel dysmotility and enteric neuron degeneration in lysosomal storage disease mice is prevented by gene therapy. Neuroscience [Preprint]. doi:10.1101\/2023.05.26.542524","DOI":"10.1101\/2023.05.26.542524"},{"key":"2025082800420213000_18.1.e261648.10","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.811686","article-title":"Neuronal Ceroid Lipofuscinosis: The Multifaceted Approach to the Clinical Issues, an Overview","volume":"13","author":"Simonati","year":"2022","journal-title":"Front Neurol"},{"key":"2025082800420213000_18.1.e261648.11","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1177\/08971900221100205","article-title":"Bioavailability of Orally Administered Drugs in Critically Ill Patients","volume":"36","author":"Forsberg","year":"2023","journal-title":"J Pharm Pract"},{"key":"2025082800420213000_18.1.e261648.12","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/17425255.2019.1575361","article-title":"Pharmacokinetic considerations for anti-epileptic drugs in children","volume":"15","author":"Verrotti","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2025082800420213000_18.1.e261648.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2012.12.007"},{"key":"2025082800420213000_18.1.e261648.14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11095-016-2033-y","article-title":"Clinical Pharmacology Studies in Critically Ill Children","volume":"34","author":"Thakkar","year":"2017","journal-title":"Pharm Res"},{"key":"2025082800420213000_18.1.e261648.15","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9071505","article-title":"Beta-Lactams Toxicity in the Intensive Care Unit: An Underestimated Collateral Damage?","volume":"9","author":"Roger","year":"2021","journal-title":"Microorganisms"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2024-261648","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T07:42:10Z","timestamp":1756366930000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2024-261648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,29]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/bcr-2024-261648"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2024-261648","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}